Trump presidency signals potential downturn in NIH SBIR/STTR grant funding for biopharma drugs
US President Donald Trump kicked off his second term with a series of directives aimed at the US National Institutes of Health (NIH), signalling headwinds in securing NIH grant funding for biopharmaceutical research and development (R7D).
US President Donald Trump kicked off his second term with a series of directives aimed at the US National Institutes of Health (NIH), signalling headwinds in securing NIH grant funding for biopharmaceutical research and development (R7D).
What's Your Reaction?
